Medicine:DelNS1-2019-nCoV-RBD-OPT
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | viral |
| Clinical data | |
| Trade names | Pneucolin |
| Other names | DelNS1-nCoV-RBD LAIV[1] |
| Routes of administration | Intranasal |
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[2][3][4]
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[5]
References
- ↑ A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19. United States National Library of Medicine. 29 April 2021. https://clinicaltrials.gov/ct2/show/NCT04809389. Retrieved 3 May 2021.
- ↑ "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. http://www.xinhuanet.com/english/2021-06/11/c_1310003298.htm.
- ↑ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". Chinese Clinical Trial Registry. https://clinicaltrials.gov/ct2/show/NCT04809389.
- ↑ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". Chinese Clinical Trial Registry. http://www.chictr.org.cn/showprojen.aspx?proj=63754.
- ↑ "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" (in zh). National Health Commission. 2022-12-14. http://www.nhc.gov.cn/xcs/zhengcwj/202212/acd8ba68d934488983909e81642dc337.shtml. Retrieved 2022-12-14.
 |
